Patients, Community Pharmacists Tell Federal Trade Commission Of CVS/Caremark Merger's Costly Side Effects More than 80 community pharmacists from the National Community Pharmacists Association (NCPA) and several patients met with the Federal Trade Commission (FTC) today to discuss the negative impact of the March 2007 CVS/Caremark merger and to urge the FTC to re-examine it.
Source: www.medicalnewstoday.comRexahn Achieves 50% Enrollment Milestone In Serdaxin™ Phase IIa Clinical Trial For Depression Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced that it has enrolled 50% of the total projected enrollment required for its Phase IIa trial to evaluate the safety and preliminary efficacy of Serdaxin™ as a central nervous system based treatment for Major Depressive Disorder (MDD). The complete trial calls for the enrollment of up to 80 patients at multiple clinical trial sites in the United States.
Source: www.medicalnewstoday.comSeattle Genetics To Present SGN-35 And Lintuzumab Clinical Data At The European Hematology Association Congress Seattle Genetics, Inc. (Nasdaq:SGEN) announced that data from a phase I clinical trial evaluating every three week dosing of SGN-35 and a phase I clinical trial of lintuzumab (SGN-33) will be reported at the 14th Congress of the European Hematology Association (EHA) being held June 4-7, 2009 in Berlin, Germany. The abstracts are available from the EHA website at http://www.ehaweb.org.
Source: www.medicalnewstoday.com
# posted by Network @ 5:51 PM
